zenocutuzumab
merus
['nsclc', 'sclc', 'zenocutuzumab']
nrg1 fusions are part of the nsclc drivers family!! zenocutuzumab, a her2-her3 bispecific antibody, has significant activity in a nrg1+ tumor agnostic population (n=83), ~50% being nsclc. orr=34% overall and 35% in nsclc. median dor 9.1 mo and favorable safety profile. #asco22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.